MediWound Ltd. (NASDAQ:MDWD - Get Free Report) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $17.65 and traded as low as $16.25. MediWound shares last traded at $16.93, with a volume of 81,062 shares.
Wall Street Analyst Weigh In
A number of research firms have recently commented on MDWD. Craig Hallum assumed coverage on shares of MediWound in a report on Friday, February 28th. They set a "buy" rating and a $39.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of MediWound in a research note on Friday, January 10th.
Read Our Latest Research Report on MDWD
MediWound Price Performance
The stock has a 50 day moving average price of $18.04 and a two-hundred day moving average price of $17.61. The company has a market capitalization of $185.63 million, a price-to-earnings ratio of -5.93 and a beta of 0.82.
Institutional Investors Weigh In On MediWound
Institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Management LLC acquired a new stake in MediWound during the 3rd quarter worth $89,000. Investor AB bought a new stake in MediWound in the third quarter valued at about $15,750,000. Point72 Asset Management L.P. acquired a new position in MediWound in the third quarter valued at about $212,000. State Street Corp boosted its holdings in MediWound by 219.6% during the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company's stock worth $1,197,000 after buying an additional 45,529 shares during the last quarter. Finally, Barclays PLC grew its position in shares of MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company's stock worth $202,000 after buying an additional 8,449 shares during the period. 46.83% of the stock is owned by institutional investors.
MediWound Company Profile
(
Get Free Report)
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Read More
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
